Clinical Trials Logo

Anxiety Disorders clinical trials

View clinical trials related to Anxiety Disorders.

Filter by:

NCT ID: NCT01624584 Completed - Anxiety Clinical Trials

A Study Comparing Two Treatments for Child With Anxiety

Start date: June 2012
Phase: Phase 3
Study type: Interventional

First, can exposure therapy for childhood anxiety begin earlier in the course of treatment than current treatment manuals suggest? Second, is treating childhood anxiety with exposure therapy more effective and efficient than treating childhood anxiety with relaxation training + cognitive restructuring?

NCT ID: NCT01624168 Completed - Anxiety Clinical Trials

Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults

Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the feasibility of a 10-week tai chi chuan intervention as a treatment for anxiety and sleep quality in young adults.

NCT ID: NCT01622374 Completed - Dental Anxiety Clinical Trials

Effects of "Music for the Mind" on Pre-operative Anxiety in Dentistry

Start date: January 2011
Phase: Phase 2/Phase 3
Study type: Interventional

To examine the pre-operative effect of music for the mind compared to some other styles of music in patients undergoing dental procedures.

NCT ID: NCT01616797 Completed - Depression, Anxiety Clinical Trials

A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression Across the Lifespan

Start date: February 2014
Phase: N/A
Study type: Interventional

The research proposes to use an innovative solution to shape brain circuits that support executive function and emotion reactivity -using targeted neurobehavioral intervention.

NCT ID: NCT01614041 Completed - Clinical trials for Generalized Anxiety Disorder

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

TACGAD
Start date: January 10, 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.

NCT ID: NCT01607710 Completed - Clinical trials for Generalized Anxiety Disorder

Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

fMRI
Start date: July 2012
Phase: N/A
Study type: Observational

The investigators are seeking to locate the brain regions of interest in generalized anxiety disorder (GAD) using both structural (sMRI) and functional magnetic resonance imaging (fMRI). The MRI will be used to measure changes in blood flow in the brain while at rest and while completing tasks designed to elicit symptoms of anxiety. Results from a nonclinical control group and a GAD group will be compared to determine whether they exhibit different areas of brain activity during the tasks.

NCT ID: NCT01599481 Completed - Depression Clinical Trials

Career Management to Improve Education, Employment and Retention for People With Anxiety and Depression

CAREER
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The aim of the investigation is to evaluate the effectiveness and costeffectiveness of a model of supported employment (the Individual Career Management (ICM) model) designed to help people with common mental illness return to work.

NCT ID: NCT01591720 Completed - Depression Clinical Trials

Tailored Internet-delivered Cognitive Behaviour Therapy in Primary Care

TAYLOR2
Start date: September 2010
Phase: N/A
Study type: Interventional

A tailored Internet-based cognitive-behavioural intervention is tested within a primary care clinic. Weekly measures of symptoms of depression and anxiety are obtained. Significant within-group effects are expected.

NCT ID: NCT01589575 Completed - Depression Clinical Trials

Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives

StressRéa
Start date: September 2012
Phase: N/A
Study type: Observational

The main objective of this study is to compare the rate of reported anxiety / depression (HADS >= 8) among spouses and other family members in ICU patients.

NCT ID: NCT01587833 Completed - Anxiety Disorders Clinical Trials

WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture

Start date: November 2011
Phase: N/A
Study type: Observational

The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1. Primary aim of these studies is to develop, test and disseminate methodological standards for the design, conduct and analysis of Pharmacoepidemiological (PE) studies applicable to different safety issues and using different data sources. To achieve this, results from PE studies on five key adverse events (AEs) performed in different databases will be evaluated. Therefore, emphasis will be on the methodological aspects of the studies in this protocol and not on the clinical consequences of the association under investigation. Benzodiazepines (BZDs) are one of the therapeutic groups most widely used, mainly indicated as hypnotics and anxiolytics. Guidelines recommend treatment courses not exceeding 4-6 weeks. However, long-term treatment is highly prevalent, particularly in older people with a prevalence ranging from 15 to 30%. However, treatment is often taken as needed. Hip/femur fractures are a major cause of morbidity and mortality, impair quality of life and impose a considerable economic burden. Among people aged 50 years and older, a case-fatality rate of 20% is associated within the first year. The relationship between benzodiazepines and hip fractures remains controversial. Psychotropic medication has been traditionally associated with hip fractures. Among psychotropic medication, long elimination half-life benzodiazepines were found to increase the risk of hip fractures in a case-control study published in the late eighties. Since then, several investigations have been performed, mostly in older patients focusing on the relationship between benzodiazepines and hip fractures, and between benzodiazepines and falls as a mechanism underlying this effect. A review performed in 2003, which included 11 epidemiological studies, reported that results were not always consistent. Seven out of eight cohort and population based case-control studies, found an association, but different results were reported according to benzodiazepines' half-life. In four hospital-based case-control studies no association between benzodiazepines use and hip fracture has been described. Data on dosing was only included in three of the studies, and once more results were not conclusive. Results ranged from no effect to an increased risk with high dose regimens. Results from subsequent succeeding studies have also shown contradictions, with no association reported in one of the studies, and an association described for the short-term use of short half-life, high-potency benzodiazepines. Even though there is epidemiological evidence suggesting that the use of benzodiazepines increases the risk of hip fractures, problems rise with the definition of benzodiazepine exposure, or biases such as confounding by indication and the control for confounders. These remain unresolved topics that should be addressed in future studies. In the present protocol, it is proposed to further asses the risk of hip/femur fractures associated with benzodiazepines using different study designs in different primary databases, and to compare the results in order to evaluate the impact of design and population differences on the outcome of the study association. The objective of this study is to assess the association between benzodiazepines use and hip/femur fracture with different study designs (descriptive, cohort, nested case-control, case crossover and self control case series) across different primary care databases (Bavarian, Mondriaan, National Databases (Denmark), General Practice Research Database (GPRD), Base de Datos para la Investigación Farmacoepidemiologica en Atencion Primaria (BIFAP) and The Health Improvement Network (THIN)) and to compare the results between databases, across designs to evaluate the impact of design/database/population differences on the outcome of the studied association.